Over 1,100 pharmaceutical companies - including 17 of the top 20 - rely on Microfluidizer processors as the undisputed gold standard for uniform particle size reduction for nanoemulsions, dispersions, nanoencapsulation and cell disruption. Customers such as Abbott Laboratories, Bristol-Myers Squibbb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough and Wyeth use our 10 pharma models to develop and produce well-known drugs and vaccines on the market today.
The overall satisfaction which we experienced with our laboratory model Microfluidizer processor eliminated the need to consider other equipment when it was time to scale up to production capabilities - Amylin Pharmaceuticals
Prescription for Success
From startups to contract manufacturers to global pharma, nearly two-thirds of the more than 3,000 Microfluidizer processors installed worldwide are used for biopharmaceutical applications. By reducing particle size uniformly, Microfluidics helps pharmaceutical leaders improve the quality, bioavailability, stability and process efficiency of their drugs. Our processors also enable researchers to accomplish the previously impossible, such as innovative methods for targeted drug delivery using multifunctional nanomedicine (webinar) and bottom-up crystallization using Microfluidics Reaction Technology (MRT).
Services and Support
Microfluidics has more than 25 years of experience working with pharmaceutical companies and understands their specific requirements. In addition to providing premium equipment for high-end and complex APIs, we also offer value-added services to support your success:
Interested in papers and presentations detailing what pharmaceutical companies have accomplished using Microfluidizer processors? Curious how we can help develop and optimize your API for production? Contact us to learn more.